Targeted Genetics (NASDAQ:TGEND)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Targeted Genetics Charts. Click Here for more Targeted Genetics Charts.](/p.php?pid=staticchart&s=N%5ETGEND&p=8&t=15)
Targeted Genetics Corporation (Nasdaq:TGEND) is
reporting new developments in its portfolio of AAV manufacturing
capabilities at the American Society of Gene Therapy (ASGT) 2006
Annual Meeting. One advance, reported yesterday afternoon in a poster,
titled "Clearance of Helper Adenovirus by an AAV1 Clinical Vector
Manufacturing Process" (Abstract #312), describes a robust method for
producing adeno-associated virus type 1 (AAV1) vectors. The other,
which will be presented today in a poster, titled "Improving the
Stability of Ad-AAV Hybrid Vectors" (Abstract #499), enables another
proprietary, scalable AAV manufacturing process that may be applicable
to commercial production.
"Targeted Genetics' leadership in designing and manufacturing
AAV-based products is a defining core competency for our company, and
one that continues to generate new product and revenue opportunities,"
said H. Stewart Parker, president and chief executive officer at
Targeted Genetics. "Our ongoing innovation of proprietary manufacture
of AAV vectors of high purity raises industry standard for
manufacturing AAV-based products using commercially relevant
processes. This strengthens our ability to commercialize novel
therapies, enhances our competitive position and establishes us as the
partner of choice for companies seeking to access AAV development and
manufacturing capabilities."
Abstract #312 describes a process for large-scale manufacturing of
vectors with AAV type 1 (AAV1) capsid proteins. AAV1 vectors, and
other AAV vectors engineered to produce AAV1 capsid proteins may
possess advantageous properties in some clinical settings compared
with the AAV2 vectors that have been evaluated in clinical trials to
date. The process also enables the effective and robust removal of
"helper" viruses used in the production of AAV vectors. The use of
multiple separation techniques removes helper virus from the vector
preparation and a robust heat inactivation step disables any remaining
helper virus without affecting the activity of AAV vectors. This
method allows for removal of helper virus in quantities that are
significantly greater than the amount of helper virus used in the
manufacturing process.
Abstract #499 describes a scaleable adenovirus (Ad)-AAV hybrid
process of manufacturing AAV. In this method, a hybrid virus that
contains AAV sequences, Ad sequences and a gene of choice is used in
the manufacturing process of AAV vectors. Modifications of the AAV
construct have been made to improve the stability of the Ad-hybrid
virus, making this process more relevant for commercial scale
applications.
About Targeted Genetics
Targeted Genetics Corporation is a biotechnology company committed
to the development and commercialization of innovative, targeted
molecular therapies for the prevention and treatment of inflammatory
arthritis, HIV/AIDS and other acquired and inherited diseases with
significant unmet medical need. Targeted Genetics uses its
considerable knowledge and capabilities in the development and
manufacturing of gene delivery technologies to advance a diverse
product development pipeline. Its product development efforts target
inflammatory arthritis, HIV/AIDS, congestive heart failure,
Huntington's disease, and hyperlipidemia. To learn more about Targeted
Genetics, visit its website at www.targetedgenetics.com.
Safe Harbor Statement under the Private Securities Litigation
Reform Act of 1995:
This release contains forward-looking statements regarding our
intellectual property, research programs and clinical trials, our
product development and our potential development platforms including
AAV vectors and other statements about our plans, objectives,
intentions and expectations and other statements about our plans,
objectives, intentions and expectations. These statements, involve
current expectations, forecasts of future events and other statements
that are not historical facts. Inaccurate assumptions and known and
unknown risks and uncertainties can affect the accuracy of
forward-looking statements. Factors that could affect our actual
results include, but are not limited to, results of animal research
are not necessarily indicative of results in humans, the timing,
nature and results of our research, potential development of
alternative technologies or more effective products by competitors,
our ability to obtain and maintain regulatory or institutional
approvals, our ability to obtain, maintain and protect our
intellectual property and our ability to raise capital when needed, as
well as other risk factors described in Item 1A. Risk Factors in our
report on Form 10-K for the year ended December 31, 2005, and updated
in Item 1A. Risk Factors in our Form 10-Q for the quarter ended March
31, 2006. You should not rely unduly on these forward-looking
statements, which apply only as of the date of this release. We
undertake no duty to publicly announce or report revisions to these
statements as new information becomes available that may change our
expectations.